Expression of transforming growth factor α antisense mRNA inhibits the estrogen‐induced production of TGFα and estrogen‐induced proliferation of estrogen‐responsive human breast cancer cells
Nicholas J. Kenney(Howard University), David Salomon(National Cancer Institute), N. Kim(National Cancer Institute), Agnes Day(Howard University), Nicola Normanno(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Fortunato Ciardiello(University of Naples Federico II), Mary Beth Martin(Georgetown University), Pilar García-Morales(Georgetown University), Toshiaki Saeki(Hiroshima University), Marco M. Gottardis(Georgetown University), Mary Lou Cutler(Uniformed Services University of the Health Sciences)
Cited by 54
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and <i>RAS</i> Mutations in Colorectal Cancer
|Journal of Clinical Oncology|2015|795